KPTI News and Press, Karyopharm Therapeutics Inc. From 12/21/21

Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology...

Karyopharm's Partner Antengene Receives Approval in China for XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma PR Newswire NEWTON, Mass. , Dec. 17, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nas...

Karyopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition -- 40% of Patients with Myelofibrosis Who Received at Least 24 Weeks of Selinexor Treatment Achieved a Resp...

Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors PR Newswire NEWTON, Mass. , Dec. 6, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therap...

Karyopharm Announces Dosing of First Patient in a New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis PR Newswire NEWTON, Mass. , Dec. 6, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI)...

Karyopharm Therapeutics reported their Q3 earnings with a beat on revenue and a slight miss on EPS. The company revealed that XPOVIO is making inroads into multiple myeloma. Despite the encouraging earnings, the ticker has been sucked into the small-cap sell-off. I am looking to take ...

COMPASS Pathways (NASDAQ:CMPS) has appointed Michael Falvey as Chief Financial Officer, suceeding Piers Morgan, effective 1 January 2022. Michael Falvey, most recently served at Karyopharm Therapeutics (NASDAQ:KPTI), where he led the financial strategy and prepared the financial inf...

Karyopharm Therapeutics (NASDAQ:KPTI) announces the completion of patient recruitment in Phase 3 SIENDO study evaluating the efficacy and safety for front-line maintenance therapy with selinexor in patients with advanced or recurrent endometrial cancer. Top-line data from this event-driv...

Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer - Top-Line Study Results Expected by End of 2021 or Early 2022 - PR Newswire NEWTON, Mass. , Dec. 2, 2021 /PRNewswire/ -- Karyopharm Therapeutics...

Karyopharm to Host Virtual Investor Day on December 8, 2021 PR Newswire NEWTON, Mass. , Dec. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will ...